Table 2.
Multivariate analyses for CK5 expression. CI, confidence interval; HR, hazard ratio; pT, pathological tumor stage; pN, pathological lymph node status; G, grading. The bold values represent significant p-values (< 0.05).
| Covariate | CK5 | |
|---|---|---|
| HR (95% CI) | p - value | |
| Total cohort | ||
| Age | 1.02 (1.01–1.03) | < 0.001 |
| Sex | 0.67 (0.48–0.92) | 0.014 |
| pT | 1.32 (1.15–1.53) | < 0.001 |
| pN | 2.55 (2.03–3.21) | < 0.001 |
| Neoadjuvant treatment | 1.11 (0.88–1.41) | 0.372 |
| CK5 expression | 1.43 (1.01–2.02) | 0.043 |
| Primary surgery cohort | ||
| Age | 1.04 (1.01–1.06) | < 0.001 |
| Sex | 0.59 (0.32–1.08) | 0.885 |
| pT | 1.68 (1.28–2.22) | < 0.001 |
| pN | 2.68 (1.65–4.35) | < 0.001 |
| G | 1.14 (0.76–1.70) | 0.526 |
| CK5 expression | 0.88 (0.37–2.06) | 0.763 |
| Neoadjuvant cohort | ||
| Age | 1.01 (1.00-1.02) | 0.065 |
| Sex | 0.71 (0.48–1.04) | 0.078 |
| pT | 1.10 (0.93–1.31) | 0.266 |
| pN | 2.36 (1.82–3.07) | < 0.001 |
| CK5 expression | 1.48 (1.02–2.15) | 0.040 |